FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2624952492> ?p ?o ?g. }

• W2624952492 abstract "ED01-01 Our improved understanding of the molecular basis of malignancy has led to the identification of many new biochemical targets for therapy. While some of the drugs developed to affect specific targets have demonstrated activity in clinical trials and have subsequently gained FDA approval, many questions remain about the optimal way to translate basic research observations into clinical practice. These questions include preclinical identification of therapeutically relevant targets with high fidelity and demonstration of clinical benefit in well-designed controlled clinical trials. There are even more vexing concerns as to whether incorporation of biomarkers or imaging studies into our current clinical trial designs will optimize the development of targeted agents and whether a subset of such biomarkers can be validated as surrogate markers for clinical benefit. Such optimization could lead to an increase in the percentage of novel agents entering phase I trials that ultimately gain FDA approval or increasing the speed with which novel agents move through the various phases of drug development. Previous publications (1, 2) suggest that measurement of drug effects in tumor or surrogate tissue or use of functional imaging studies have not improved the efficiency of phase I clinical trials and did not contribute to the selection of a dose for phase II study. Likewise, limited data from phase II efficacy studies of targeted agents typically employed a standard primary endpoint such as objective response with only a limited number of studies qualifying patients for therapy through measurement of target expression or use of enrichment designs. No phase II studies used measurement of a surrogate endpoint to assess anticancer drug effects with, or in place of, clinical endpoints (3). Despite the practical challenges highlighted by these data, effectively incorporating translational endpoints into early clinical trials of novel targeted agents remains appealing and suggests that clinical trials with translational endpoints require more extensive planning to demonstrate their relevance. We will consider how appropriate planning can begin to address the challenges inherent in designing successful translational clinical trials that contribute essential information to drug development and ultimately facilitate the approval of targeted anticancer agents.
 References
 Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: Theory and practice. J Natl Cancer Inst 2004;96:990-7. Goulart BHL, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA. Trends in the use and role of biomarkers in Phase I oncology trials. Clin Cancer Res 2007;13:6719-26. El-Maraghi RH, Eisenhauer EA. Review of Phase II trial designs used in studies of molecular targeted agents: Outcomes and predictors of success in Phase III. J Clin Oncol 2008;26:1346-54." @default.
• W2624952492 created "2017-06-23" @default.
• W2624952492 creator A5087376683 @default.
• W2624952492 date "2008-08-01" @default.
• W2624952492 modified "2023-09-27" @default.
• W2624952492 title "Translational clinical trial design" @default.
• W2624952492 hasPublicationYear "2008" @default.
• W2624952492 type Work @default.
• W2624952492 sameAs 2624952492 @default.
• W2624952492 citedByCount "0" @default.
• W2624952492 crossrefType "journal-article" @default.
• W2624952492 hasAuthorship W2624952492A5087376683 @default.
• W2624952492 hasConcept C128544194 @default.
• W2624952492 hasConcept C141341695 @default.
• W2624952492 hasConcept C142724271 @default.
• W2624952492 hasConcept C143998085 @default.
• W2624952492 hasConcept C148482608 @default.
• W2624952492 hasConcept C177713679 @default.
• W2624952492 hasConcept C19527891 @default.
• W2624952492 hasConcept C203092338 @default.
• W2624952492 hasConcept C2780035454 @default.
• W2624952492 hasConcept C31760486 @default.
• W2624952492 hasConcept C502991105 @default.
• W2624952492 hasConcept C535046627 @default.
• W2624952492 hasConcept C60644358 @default.
• W2624952492 hasConcept C64903051 @default.
• W2624952492 hasConcept C71924100 @default.
• W2624952492 hasConcept C86803240 @default.
• W2624952492 hasConcept C98274493 @default.
• W2624952492 hasConceptScore W2624952492C128544194 @default.
• W2624952492 hasConceptScore W2624952492C141341695 @default.
• W2624952492 hasConceptScore W2624952492C142724271 @default.
• W2624952492 hasConceptScore W2624952492C143998085 @default.
• W2624952492 hasConceptScore W2624952492C148482608 @default.
• W2624952492 hasConceptScore W2624952492C177713679 @default.
• W2624952492 hasConceptScore W2624952492C19527891 @default.
• W2624952492 hasConceptScore W2624952492C203092338 @default.
• W2624952492 hasConceptScore W2624952492C2780035454 @default.
• W2624952492 hasConceptScore W2624952492C31760486 @default.
• W2624952492 hasConceptScore W2624952492C502991105 @default.
• W2624952492 hasConceptScore W2624952492C535046627 @default.
• W2624952492 hasConceptScore W2624952492C60644358 @default.
• W2624952492 hasConceptScore W2624952492C64903051 @default.
• W2624952492 hasConceptScore W2624952492C71924100 @default.
• W2624952492 hasConceptScore W2624952492C86803240 @default.
• W2624952492 hasConceptScore W2624952492C98274493 @default.
• W2624952492 hasLocation W26249524921 @default.
• W2624952492 hasOpenAccess W2624952492 @default.
• W2624952492 hasPrimaryLocation W26249524921 @default.
• W2624952492 hasRelatedWork W1549144603 @default.
• W2624952492 hasRelatedWork W1964602837 @default.
• W2624952492 hasRelatedWork W1985598595 @default.
• W2624952492 hasRelatedWork W1989660002 @default.
• W2624952492 hasRelatedWork W1994373725 @default.
• W2624952492 hasRelatedWork W2028453270 @default.
• W2624952492 hasRelatedWork W2038644375 @default.
• W2624952492 hasRelatedWork W2043297836 @default.
• W2624952492 hasRelatedWork W2076809452 @default.
• W2624952492 hasRelatedWork W2118145600 @default.
• W2624952492 hasRelatedWork W2128666233 @default.
• W2624952492 hasRelatedWork W2135933713 @default.
• W2624952492 hasRelatedWork W2223585524 @default.
• W2624952492 hasRelatedWork W2409117897 @default.
• W2624952492 hasRelatedWork W2470067656 @default.
• W2624952492 hasRelatedWork W2612014585 @default.
• W2624952492 hasRelatedWork W2612229386 @default.
• W2624952492 hasRelatedWork W3170928901 @default.
• W2624952492 hasRelatedWork W2133425730 @default.
• W2624952492 hasRelatedWork W3023626110 @default.
• W2624952492 hasVolume "14" @default.
• W2624952492 isParatext "false" @default.
• W2624952492 isRetracted "false" @default.
• W2624952492 magId "2624952492" @default.
• W2624952492 workType "article" @default.